Fragile X syndrome is caused by a mutation on the X chromosome and is the most common inherited cause of intellectual disability. It causes intellectual disabilities and behavioral issues in affected individuals. While premutation carriers do not usually show symptoms, they have an increased risk of fragile X-associated tremor/ataxia syndrome (FXTAS) or premature ovarian failure. There are no cures for fragile X syndrome, so treatment focuses on education and managing behavioral problems. The risk of having an affected child depends on factors like the size of the parent's premutation and the sex of the child.
Fragile X syndrome is caused by a mutation on the X chromosome and is the most common inherited cause of intellectual disability. It causes intellectual disabilities and behavioral issues in affected individuals. While premutation carriers do not usually show symptoms, they have an increased risk of fragile X-associated tremor/ataxia syndrome (FXTAS) or premature ovarian failure. There are no cures for fragile X syndrome, so treatment focuses on education and managing behavioral problems. The risk of having an affected child depends on factors like the size of the parent's premutation and the sex of the child.
Fragile X syndrome is caused by a mutation on the X chromosome and is the most common inherited cause of intellectual disability. It causes intellectual disabilities and behavioral issues in affected individuals. While premutation carriers do not usually show symptoms, they have an increased risk of fragile X-associated tremor/ataxia syndrome (FXTAS) or premature ovarian failure. There are no cures for fragile X syndrome, so treatment focuses on education and managing behavioral problems. The risk of having an affected child depends on factors like the size of the parent's premutation and the sex of the child.
Fragile X syndrome is caused by a mutation on the X chromosome and is the most common inherited cause of intellectual disability. It causes intellectual disabilities and behavioral issues in affected individuals. While premutation carriers do not usually show symptoms, they have an increased risk of fragile X-associated tremor/ataxia syndrome (FXTAS) or premature ovarian failure. There are no cures for fragile X syndrome, so treatment focuses on education and managing behavioral problems. The risk of having an affected child depends on factors like the size of the parent's premutation and the sex of the child.
common, progression to a full mutation has been observed No curative treatments are currently available for fragile X only on a limited number of haplotypes; that is, there is a syndrome. Therapy focuses on educational intervention and hap_l�type predisposition to expansion. This haplotype predis pharmacological management of the behavioral problems. posmon may relate partly to the presence of a few AGG triplets embedded within the string of CGG repeats· these AGG triplets appear to inhibit expansion of the string ;f CGG INHERITANCE RISK repeats, and their absence in some haplotypes therefore may predispose to expansion. The risk that a woman with a premutation will have an affected child is determined by the size of the premutation, the sex of the fetus, and the family history. Empirically, the risk Phenotype and Natural History to a premutation carrier of having an affected child can be as high as 50% for each male child and 25% for each female Fragile X syndrome causes moderate intellectual disability in child but depends on the size of the premutation. On the basis affected males and mild intellectual deficits in affected females. of analysis of a relatively small number of carrier mothers, the Most affected individuals also have behavioral abnormalities recurrence risk appears to decline as the premutation decreases including hyperactivity, hand flapping or biting, temper tan '. from 100 to 59 repeats. Prenatal testing is available by use of trums, poor eye contact, and autistic features. The physical fetal DNA derived from chorionic villi or amniocytes. features of males vary in relation to puberty such that before puberty, they have somewhat large heads but few other dis t�c�ive _ features; after puberty, they frequently have more d1Stmct1ve features (long face with prominent jaw and fore head, large ears, and macro-orchidism). Because these clinical REFERENCES findings are not unique to fragile X syndrome, the diagnosis depends on molecular detection of mutations. Patients with Besterman AO, Wilke SA, Milligan TE, et al Towards an understanding of neuro _ fragile X syndrome have a normal life span. psych1atnc man1festat1ons in fragile X premutation carriers, Future Neural9:227- 239, 2014. Nearly all males and 40% to 50% of females who inherit Hagerman A, Hagerman P: Advances in clinical and molecular understanding of the a full mutation will have fragile X syndrome. The severity of FMRl premutation and fragile X-associated tremor/ataxia syndrome, Lancet the phenotype depends on repeat length mosaicism and repeat Neural 12786-798, 2013. methylation (see Fig. C-17). Because full mutations are mitoti Saul RA, Tarleton JC FMR/-related disorders. Available from http://www.ncbi cally unstable, some patients have a mixture of cells with .nlm.nih gov/books/NB Kl 384/ repeat lengths ranging from premutation to full mutation Tassone F: Newborn screening for fragile X syndrome, JAMA Neural 71355-359, (repeat length mosaicism). All males with repeat length mosa 2014. icism are affected but often have higher mental function than those with a full mutation in every cell; females with repeat lenrh mosaicism _ are normal to fully affected. Similarly, some patients have a rruxture of cells, with and without methylation of the CGG repeat (repeat methylation mosaicism). All males with methylation mosaicism are affected but often have higher mental function than those with a hypermethylation in every cell; females with methylation mosaicism are normal to fully affected. Very rarely, patients have a full mutation that is unmethylated in all cells; whether male or female, these patients vary from normal to fully affected. In addition, in females, the phenotype is dependent on the degree of skewing of X chromosome inactivation (see Chapter 6). Female carriers of premutations (but not full mutations) are_ at a 20:o risk for �remature ovarian failure. Male premu tat10n earners are at nsk for the fragile X associated tremor/ ataxia syndrome (FXTAS). FXTAS manifests as late-onset progressive cerebellar ataxia and intention tremor. Affected individuals may also have loss of short-term memory execu tive function, and cognition as well as parkinsonism,' periph eral neuropathy, lower limb proximal muscle weakness and autonomic dysfunction. Penetrance of FXTAS is age '. dependent, manifesting in 17% in the sixth decade, in 38% m the seventh decade, in 47% in the eighth decade, and in thm: fourths of those older than 80 years. FXTAS may mani fest m some female premutation carriers.